XBI241220C105000
- 0.01
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
SPDR S&P Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 0.00269 USD Dividend Per Share
December 20th (Eastern Time) - $SPDR S&P Biotech ETF(XBI.US)$ is trading ex-dividend on December 23rd, 2024.Shareholders of record on December 23rd, 2024 will receive 0.00269 USD dividend per share
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
Vertex Announces U.S. FDA Approval For TRIKAFTA To Include Additional Non-F508del TRIKAFTA-Responsive Variants
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520
J.P. Morgan's Top Healthcare Stocks for 2025
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Neurocrine Biosciences Analyst Ratings
Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold
The Dow barely ended its longest continuous decline in 50 years, Micron fell by 16%, the US dollar reached a two-year high again, and US bonds, oil, and Bitcoin all dropped.
U.S. stock market's other Indexes turned down towards the end, Tesla rose by nearly 4% before closing down, NVIDIA reached a high of 4%, and Micron Technology had its steepest decline in five years. The yield on the 10-year U.S. Treasury bonds briefly increased by nearly 10 basis points approaching 4.60%, close to a seven-month high, while short-term bond yields fell, with the 2/10-year yield spread at its widest in two and a half years. The Bank of England held rates steady, but more officials supported a rate cut, leading to a decline in the British Pound. The Governor of the Bank of Japan suppressed interest rate hike expectations, causing the yen to fall towards 158, and the offshore renminbi briefly dropped below 7.32 yuan to its lowest in 15 months. Bitcoin fell by 5%, approaching $0.096 million. Spot Gold rose by 1.6% before narrowing back below $2,600, while the futures silver fell by 5%, and U.S. crude oil fell below $70.
Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
12 Health Care Stocks Moving In Thursday's Pre-Market Session
The Analyst Verdict: Incyte In The Eyes Of 15 Experts
(GILD) - Analyzing Gilead Sciences's Short Interest
Vertex Downgraded to Perform by Oppenheimer
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Vertex Pharmaceuticals Analyst Ratings
25 U.S. 'Highest Conviction' Stocks – UBS
Gilead Raises Assembly Bio Stake to ~30%
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts